MedTrace Logo

Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting

NCT00246740 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2017-12-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass (CPB).

Conditions

  • Coronary Artery Bypass Grafting
  • Cardiopulmonary Bypass
  • Reperfusion Injury

Interventions

DRUG

Periostat

In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

DRUG

Placebo Oral Tablet

In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Barry A Finegan, FFARCS FRCPC · Department of Anesthesiology and Pain Medicine, University of Alberta Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-05-31
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00246740 on ClinicalTrials.gov